Johnson & Johnson

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JNJ and other ETFs, options, and stocks.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.

CEO

Joaquin Duato

CEOJoaquin Duato

Employees

131,900

Employees131,900

Headquarters

New Brunswick, New Jersey

HeadquartersNew Brunswick, New Jersey

Founded

1887

Founded1887

Employees

131,900

Employees131,900

JNJ Key Statistics

Market cap

372.24B

Market cap372.24B

Price-Earnings ratio

22.27

Price-Earnings ratio22.27

Dividend yield

3.08%

Dividend yield3.08%

Average volume

6.59M

Average volume6.59M

High today

$155.00

High today$155.00

Low today

$153.71

Low today$153.71

Open price

$154.81

Open price$154.81

Volume

6.51M

Volume6.51M

52 Week high

$175.97

52 Week high$175.97

52 Week low

$143.13

52 Week low$143.13

JNJ News

Seeking Alpha 21h

Novo Nordisk, J&J lead R&D rankings in big pharma: report

Weight loss drugmaker Novo Nordisk (NVO) and U.S. healthcare giant Johnson & Johnson (NYSE:JNJ) have become the most transformative companies in big pharma, acc...

Seeking Alpha 1d

Johnson & Johnson-backed Rapport Therapeutics files for $100M IPO

Rapport Therapeutics, a clinical-stage biopharma backed by the venture capital arm of Johnson & Johnson (NYSE:JNJ), submitted SEC filings on Friday to raise up...

NBC News 1d

Study links talc use to ovarian cancer — a potential boon for thousands suing J&J - NBC News

New research published this week lends credence to the more than 50,000 lawsuits against Johnson & Johnson that allege its talc-based baby powder caused ovarian...

Analyst ratings

52%

of 23 ratings

Buy

47.8%

Hold

52.2%

Sell

More JNJ News

Simply Wall St 2d

Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution

The fact that multiple Johnson & Johnson (NYSE:JNJ) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongs...

Reuters 2d

J&J-backed startup Rapport files for US IPO

(Reuters) -Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson, filed for an initial public offering in the U...

Financial Times 2d

‘Reverse Yankee’ deals boom as Europe’s low borrowing costs lure US groups

Print this page US companies are flocking to Europe’s bond markets as an uptick in cross-border mergers and acquisitions and a rethink on the path of interest...

Yahoo Finance 3d

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M - Yahoo Finance

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix...

Yahoo Finance 3d

Johnson & Johnson Up 5.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance

A month has gone by since the last earnings report for Johnson & Johnson (JNJ). Shares have added about 5.5% in that time frame, underperforming the S&P 500. W...

Seeking Alpha 3d

Johnson & Johnson to buy dermatology-focused biotech Proteologix

Johnson & Johnson (NYSE:JNJ) announced Thursday an agreement to acquire Proteologix, a privately held biotech focused on developing drugs for the immune-mediate...

Reuters 3d

UPDATE 1-Johnson & Johnson to acquire Proteologix for $850 million

(Adds details on Proteologix's drug in paragraph 2, and J&J drug in paragraph 4) May 16 (Reuters) - Johnson & Johnson said on Thursday it would acquire Proteol...